DERMATA THERAPEUTICS, INC. Stock-Based Compensation
DERMATA THERAPEUTICS, INC. (DRMA) reported Stock-Based Compensation of $41.78 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- DERMATA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $41.78K, a 6.49% increase year-over-year.
- DERMATA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $43.28K, a 16.37% increase year-over-year.
- DERMATA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $29.47K, a 1.16% decline year-over-year.
- DERMATA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $37.84K, a 80.26% increase year-over-year.
- DERMATA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $143.73K, a 78.14% decline from fiscal 2024.
- DERMATA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $657.65K, a 25.97% increase from fiscal 2023.
- DERMATA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $522.08K, a 43.88% decline from fiscal 2022.
- DERMATA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $930.33K, a 51.17% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.78K 10-Q · filed 2026-08-11 | $85.06K 10-Q · filed 2026-08-11 | $114.53K derived: sum of 3 quarters · filed 2026-08-11 | $152.37K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $43.28K 10-Q · filed 2026-05-13 | $72.75K derived: sum of 2 quarters · filed 2026-05-13 | $110.59K derived: sum of 3 quarters · filed 2026-05-13 | $149.82K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $29.47K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $67.31K derived: sum of 2 quarters · filed 2026-03-26 | $106.54K derived: sum of 3 quarters · filed 2026-08-11 | $143.73K 10-K · filed 2026-03-26 |
| 2025-09-30 | $37.84K 10-Q · filed 2025-11-14 | $77.07K derived: sum of 2 quarters · filed 2026-08-11 | $114.26K 10-Q · filed 2025-11-14 | $144.08K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $39.23K 10-Q · filed 2026-08-11 | $76.42K 10-Q · filed 2026-08-11 | $106.24K derived: sum of 3 quarters · filed 2026-08-11 | $127.23K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $37.19K 10-Q · filed 2026-05-13 | $67.00K derived: sum of 2 quarters · filed 2026-05-13 | $88.00K derived: sum of 3 quarters · filed 2026-05-13 | $107.60K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $29.82K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $50.81K derived: sum of 2 quarters · filed 2026-03-26 | $70.42K derived: sum of 3 quarters · filed 2026-03-26 | $657.65K 10-K · filed 2026-03-26 |
| 2024-09-30 | $20.99K 10-Q · filed 2025-11-14 | $40.60K derived: sum of 2 quarters · filed 2025-11-14 | $627.83K 10-Q · filed 2025-11-14 | $756.30K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $19.61K 10-Q · filed 2025-08-13 | $606.84K 10-Q · filed 2025-08-13 | $735.31K derived: sum of 3 quarters · filed 2025-08-13 | $866.49K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $587.23K 10-Q · filed 2025-05-14 | $715.70K derived: sum of 2 quarters · filed 2025-05-14 | $846.88K derived: sum of 3 quarters · filed 2025-05-14 | $978.06K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $128.47K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $259.64K derived: sum of 2 quarters · filed 2025-03-17 | $390.82K derived: sum of 3 quarters · filed 2025-03-17 | $522.08K 10-K · filed 2025-03-17 |
| 2023-09-30 | $131.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $262.35K derived: sum of 2 quarters · filed 2024-11-13 | $393.61K 10-Q · filed 2024-11-13 | $614.50K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $131.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $262.44K 10-Q · filed 2024-08-07 | $483.33K derived: sum of 3 quarters · filed 2024-08-07 | $718.31K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $131.26K 10-Q · filed 2024-05-15 | $352.15K derived: sum of 2 quarters · filed 2024-05-15 | $587.13K derived: sum of 3 quarters · filed 2024-05-15 | $848.71K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $220.89K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $455.87K derived: sum of 2 quarters · filed 2024-03-21 | $717.45K derived: sum of 3 quarters · filed 2024-03-21 | $930.33K 10-K · filed 2024-03-21 |
| 2022-09-30 | $234.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $496.56K derived: sum of 2 quarters · filed 2023-11-09 | $709.43K 10-Q · filed 2023-11-09 | $1.20M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $261.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $474.45K 10-Q · filed 2023-08-10 | $963.17K derived: sum of 3 quarters · filed 2023-08-10 | $1.11M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $212.88K 10-Q · filed 2023-05-11 | $701.60K derived: sum of 2 quarters · filed 2023-05-11 | $844.25K derived: sum of 3 quarters · filed 2023-05-11 | $958.24K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $488.72K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $631.37K derived: sum of 2 quarters · filed 2023-02-21 | $745.36K derived: sum of 3 quarters · filed 2023-02-21 | $1.91M 10-K · filed 2023-02-21 |
| 2021-09-30 | $142.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $256.64K derived: sum of 2 quarters · filed 2022-11-10 | $1.42M 10-Q · filed 2022-11-10 | $1.42M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $113.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $1.27M 10-Q · filed 2022-08-15 | $1.27M derived: sum of 3 quarters · filed 2022-08-15 | $1.27M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $1.16M 10-Q · filed 2022-05-16 | $1.16M derived: sum of 2 quarters · filed 2022-05-16 | $1.16M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2022-05-16 | $0.00 derived: sum of 2 quarters · filed 2022-05-16 | $0.00 10-Q · filed 2022-05-16 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |